Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RB6-8C5_Biotin_Ly-6GslashLy-6C_Antibody_1_FC_090116
C57BL/6 mouse bone marrow stained with biotinylated Ly-6G/Ly-6C (clone RB6-8C5, filled histogram) or biotinylated Rat IgG2b, κ isotype control (open histogram), followed by streptavidin PE.
  • RB6-8C5_Biotin_Ly-6GslashLy-6C_Antibody_1_FC_090116
    C57BL/6 mouse bone marrow stained with biotinylated Ly-6G/Ly-6C (clone RB6-8C5, filled histogram) or biotinylated Rat IgG2b, κ isotype control (open histogram), followed by streptavidin PE.
Compare all formats
Cat # Size Price Quantity Check Availability Save
108403 50 µg 47 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108404 500 µg 237 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with biotin under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C. Do not freeze.
Application

FC - Quality tested
IP, IHC, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Ahmed AU, et al. 2017. J Immunol. 199(6):2128. PubMed
  2. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  3. Domingues AF, et al. 2020. Elife. 9:e51754. PubMed
  4. Zhu C, et al. 2018. Sci Rep. 5.113194444. PubMed
  5. Patel MM, et al. 2018. J Am Heart Assoc. 7:e010690. PubMed
  6. Tanimura N et al. 2018. Developmental cell. 46(5):581-594 . PubMed
  7. Florentin J, et al. 2022. Front Immunol. 13:882484. PubMed
  8. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  9. Liu M, et al. 2022. J Exp Med. 219:. PubMed
  10. Lin YH, et al. 2021. Front Immunol. 12:626418. PubMed
  11. Davis FM, et al. 2020. J Immunol. 2503:204. PubMed
  12. Bouchareychas L, et al. 2021. iScience. 24(8):102847. PubMed
  13. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  14. Giambra V et al. 2018. Cell stem cell. 23(5):714-726 . PubMed
  15. Moon H et al. 2017. Cell stem cell. 21(5):665-678 . PubMed
  16. Yu VWC et al. 2016. Cell. 167(5):1310-1322 . PubMed
  17. Gutiérrez-Gutiérrez Ó, et al. 2021. EMBO Rep. 22:e52905. PubMed
  18. Scalzo S, et al. 2022. Int J Nanomedicine. 17:2865. PubMed
  19. Dubeykovskaya Z, et al. 2016. Nat Commun. 7:10517. PubMed
  20. Preglej T, et al. 2020. JCI Insight. 5(4):. PubMed
  21. Riether C, et al. 2021. Cell Reports. 34(4):108663. PubMed
  22. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  23. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  24. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
  25. Hinterbrandner M, et al. 2021. JCI Insight. 6:e151797. PubMed
  26. Li Q et al. 2018. Immunity. 48(2):258-270 . PubMed
  27. Mann M, et al. 2018. Cell Rep. 25:2992. PubMed
  28. Davis FM, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2353. PubMed
  29. Mikami H, et al. 2020. Nat Commun. 11:1162. PubMed
  30. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  31. Wu HC, et al. 2021. Cancer Discov. Online ahead of print. PubMed
  32. Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed
  33. Liu X, et al. 2021. eLife. 0.416666666666667. PubMed
  34. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  35. Dey A et al. 2019. The EMBO journal. 38(7) pii: e100293. PubMed
  36. Suah AN, et al. 2021. J Clin Invest. 131:. PubMed
  37. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  38. Sochalska M, et al. 2016. Oncogene. 10.1038/onc.2016.362. PubMed
  39. Olsson A, et al. 2016. Nature. 10.1038/nature19348. PubMed
  40. Kitano M, et al. 2016. Proc Natl Acad Sci U S A. 113: 1044 - 1049. PubMed
  41. Parada-Kusz M, et al. 2018. Dis Model Mech. 11:. PubMed
  42. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  43. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  44. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  45. Getts D, et al. 2008. J Exp Med. 205:2319. PubMed
  46. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  47. Yu VWC, et al. 2017. Cell. 168:944. PubMed
  48. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  49. Luo W et al. 2018. Immunity. 48(2):313-326 . PubMed
  50. Haase C, et al. 2022. Nat Methods. 19:1622. PubMed
  51. Kotaki R, et al. 2020. Sci Rep. 10:13554. PubMed
  52. Khiew SH, et al. 2020. J Clin Invest. 130:3453. PubMed
  53. Köchl R, et al. 2020. Elife. 9:00. PubMed
  54. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  55. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  56. Derecka M, et al. 2020. Nat Immunol. 261:21. PubMed
  57. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  58. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  59. Perez E, et al. 2020. J Immunol. 205:2489. PubMed
  60. Milner JJ, et al. 2020. Immunity. 52(5):808-824.e7. PubMed
  61. Carr M, et al. 2016. Proc Natl Acad Sci U S A. 113(52):15024-15029. PubMed
  62. Aktories P, et al. 2022. Cell Rep Methods. 2:100260. PubMed
  63. Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed
  64. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  65. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  66. Sevin M, et al. 2018. Nat Commun. 9:1431. PubMed
  67. Galle-Treger L, et al. 2020. J Allergy Clin Immunol. 145:502. PubMed
  68. Yi W, et al. 2021. Cell Reports. 34(13):108922. PubMed
  69. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  70. Goldstein JM et al. 2019. Cell reports. 27(4):1254-1264 . PubMed
  71. Akk A, et al. 2019. Mol Immunol. 114:629. PubMed
  72. Zhai X, et al. 2021. Sci Adv. 7:eabk0490. PubMed
  73. Gao Y, et al. 2020. Immunity. 52(6):1007-1021.e8. PubMed
  74. Frohner IE, et al. 2020. Cell Rep. 30:3171. PubMed
  75. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  76. Lehrke MJ, et al. 2021. Elife. 10:. PubMed
  77. Zeis P, et al. 2020. Immunity. 53:775. PubMed
  78. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  79. Nagashima H et al. 2019. Immunity. 51(4):682-695 . PubMed
  80. Shin JW, et al. 2020. Cell Death Dis. 0.667361111. PubMed
  81. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  82. He M, et al. 2020. Cell Metabolism. 31(3):580-591. PubMed
  83. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  84. Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed
  85. Roderick J, et al. 2014. Proc Natl Acad Sci U S A. 111:14436. PubMed
  86. Zhang C, et al. 2018. Cell Res. 28:323. PubMed
  87. Mohrin M, et al. 2021. Aging Cell. 20:e13313. PubMed
  88. Rai S, et al. 2022. Nat Commun. 13:5346. PubMed
  89. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  90. Michel A, et al. 2013. J Immunol. 90:5534. PubMed
  91. Lefkopoulos S, et al. 2020. Immunity. 53(5):934-951.e9. PubMed
  92. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  93. Ito K et al. 2019. Cell Rep. 28(10):2480-2490 . PubMed
  94. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  95. Morganti C, et al. 2022. EMBO Rep. 23:e54262. PubMed
  96. Riedel SS, et al. 2021. Molecular Cell. 81(11):2332-2348.e9. PubMed
  97. Lutz J, et al. 2015. Nat Commun. 6: 8575. PubMed
  98. Matsuzaki Y, et al. 2015. Biomed Rep. 1: 91 - 97. PubMed
  99. Teng Y, et al. 2021. Mol Ther. 29:2424. PubMed
  100. Mincham KT, et al. 2021. Front Immunol. 11:601494. PubMed
  101. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  102. Li ZG, et al. 2020. Chin Med J (Engl). 1943:133. PubMed
  103. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  104. Olariu V, et al. 2021. Cell Reports. 34(2):108622. PubMed
  105. Zysset D, et al. 2016. Nat Commun. 7:13151. PubMed
RRID
AB_313368 (BioLegend Cat. No. 108403)
AB_313369 (BioLegend Cat. No. 108404)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

How many biotin molecules are per antibody structure?
We don't routinely measure the number of biotins with our antibody products but the number of biotin molecules range from 3-6 molecules per antibody.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Go To Top Version: 3    Revision Date: 09.01.2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account